Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Study of Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide Progression

NCT03764540 is registered in ClinicalTrials.gov with Centre hospitalier de l'Université de Montréal (CHUM) as lead sponsor.

NCT NCT03764540
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03764540 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Study of Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide Progression
Lead sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Phase
Phase 2
Overall status
Terminated
Start date
April 1, 2019
Completion date
December 31, 2024
Enrollment
57 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic prostate cancer